COMP <GO>
REGN vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Regeneron Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: REGN 5
— LLY 10
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: LLY
LAST: $927.89 (+13.33%) • MKT CAP: $84.30B
dividend-safety
0.44%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REGN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | REGN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 32.36% | -22.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.2x | 36.4x | -16.22 | REGN | /valuation <GO> |
| Free Cash Flow Yield | 5.14% | 2.30% | +2.84 | REGN | /fcf-yield <GO> |
| Operating Margin | 24.90% | 40.21% | -15.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 31.90% | -0.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 1.00% | 45.51% | -44.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.44% | 0.49% | -0.05 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.72 | 9.29 | -1.57 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.77% | +0.63 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.1 | 77.9 | +1.23 | REGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 0.51 | +0.65 | REGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 26.3x | -8.85 | REGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $84.30B | $1.33T | -$1.25T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | REGN REV | LLY REV | REGN GROSS % | LLY GROSS % | REGN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.34B | $65.18B | 44.0% | 83.0% | $4.33B | $16.81B |
| FY 2024 | $14.20B | $45.04B | 44.0% | 81.3% | $3.78B | $8.82B |
| FY 2023 | $13.12B | $34.12B | 44.0% | 79.3% | $4.00B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REGN // BETA 1.16
LLY // BETA 0.51